Skip to Content
Merck
All Photos(1)

Key Documents

53583-U

Supelco

Ascentis® Express F5, 2.7 μm HPLC Column

2.7 μm particle size, L × I.D. 5 cm × 4.6 mm

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

material

stainless steel column

Quality Level

Agency

suitable for USP L43

product line

Ascentis®

feature

endcapped

manufacturer/tradename

Ascentis®

packaging

1 ea of

parameter

60 °C temp. range
600 bar max. pressure (9000 psi)

technique(s)

HPLC: suitable
LC/MS: suitable
UHPLC-MS: suitable
UHPLC: suitable

L × I.D.

5 cm × 4.6 mm

surface area

135 m2/g

impurities

<5 ppm metals

matrix

Fused-Core particle platform
superficially porous particle

matrix active group

PFP (pentafluorophenyl) phase

particle size

2.7 μm

pore size

90 Å pore size

operating pH

2-8

application(s)

food and beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

General description

The pentafluorophenylpropyl stationary phase of Ascentis Express F5 provides a stable reversed phase packing with electron-deficient phenyl rings due to the presence of electronegative fluorines.In addition to forming pi-pi and mildly steric interactions, F5 phases also retain compounds by polar interactions. Ascentis Express F5 can be used for basic, acidic, or neutral compounds with alternate selectivity from C18.

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Iltaf Shah et al.
The Journal of steroid biochemistry and molecular biology, 180, 118-128 (2018-02-13)
Research shows that immunoassay techniques are not the best choice for the estimation of vitamin D in human blood samples. The main reasons are that some immunoassays are not able to distinguish between 25-OHD3 and 25-OHD2 vitamin D metabolites. Furthermore

Articles

Enhanced selectivity for stereoisomers and closely related compounds with alternate selectivity from C18 phases for basic, acidic, or neutral compounds

Protocols

Fast and Accurate LC-MS Analysis of Vitamin D Metabolites, Using Ascentis® Express F5 HPLC Columns from Supelco®

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service